The present specification provides a compound having a spiro structure, and an organic light emitting device including the same.

The present specification provides a compound having a spiro structure, and an organic light emitting device including the same.

[Problem] Provided are a photoelectric conversion device and an imaging apparatus capable of improving quantum efficiency and a response speed. [Solving means] A first photoelectric conversion device according to one embodiment of the present disclosure includes a first electrode, a second electrode opposed to the first electrode, and a photoelectric conversion layer. The photoelectric conversion layer is provided between the first electrode and the second electrode and includes at least one type of one organic semiconductor material having crystallinity. Variation in a ratio between horizontally-oriented crystal and vertically-oriented crystal in the photoelectric conversion layer is three times or less between a case where film formation of the one organic semiconductor material is performed at a first temperature and a case where the film formation of the one organic semiconductor material is performed at a second temperature. The second temperature is higher than the first temperature.

Provided is a compound of Formula 1:

##STR00001## wherein: X and Y are independently O, S, or CZ1Z2; Ring A is a benzene or naphthalene ring; A1 to A4 are independently hydrogen, deuterium, a halogen group, a cyano group, a nitro group, a hydroxyl group, or a substituted or unsubstituted: alkyl, cycloalkyl, aryl, or heterocyclic group; R1 to R6, Z1, and Z2 are independently a substituted or unsubstituted: alkyl, aryl, or heterocyclic group; n1 to n3, m, and l are 0 or 1 and n1+n2+n3 is ≥2; a1 and a2 are 1 to 4; a3 is 1 to 3; a4 is 1 to 6; and when a1 to a4 are each 2 or higher, structures in the parenthesis are the same or different, provided that when Ring A is naphthalene, m is 0, and when l is 1, Ring A is a benzene ring,
and an organic light-emitting device comprising the compound.

Provided is a compound of Formula 1:

##STR00001## wherein: X and Y are independently O, S, or CZ1Z2; Ring A is a benzene or naphthalene ring; A1 to A4 are independently hydrogen, deuterium, a halogen group, a cyano group, a nitro group, a hydroxyl group, or a substituted or unsubstituted: alkyl, cycloalkyl, aryl, or heterocyclic group; R1 to R6, Z1, and Z2 are independently a substituted or unsubstituted: alkyl, aryl, or heterocyclic group; n1 to n3, m, and l are 0 or 1 and n1+n2+n3 is ≥2; a1 and a2 are 1 to 4; a3 is 1 to 3; a4 is 1 to 6; and when a1 to a4 are each 2 or higher, structures in the parenthesis are the same or different, provided that when Ring A is naphthalene, m is 0, and when l is 1, Ring A is a benzene ring,
and an organic light-emitting device comprising the compound.

This disclosure relates to picolinamides of Formula I and their use as fungicides.

##STR00001##

This disclosure relates to picolinamides of Formula I and their use as fungicides.

##STR00001##

[Problem] Provided are a photoelectric conversion device and an imaging apparatus capable of improving quantum efficiency and a response speed.

[Solving means] A first photoelectric conversion device according to one embodiment of the present disclosure includes a first electrode, a second electrode opposed to the first electrode, and a photoelectric conversion layer. The photoelectric conversion layer is provided between the first electrode and the second electrode and includes at least one type of one organic semiconductor material having crystallinity. Variation in a ratio between horizontally-oriented crystal and vertically-oriented crystal in the photoelectric conversion layer is three times or less between a case where film formation of the one organic semiconductor material is performed at a first temperature and a case where the film formation of the one organic semiconductor material is performed at a second temperature. The second temperature is higher than the first temperature.

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

##STR00001##

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

##STR00001##